Dynavax Technologies
Corporation DVAX today announced the design of its next
large-scale clinical study of HEPLISAV, its investigational adult
hepatitis B vaccine, following discussions with the U.S. Food and
Drug Administration (FDA or Agency). The planned study, HBV-23, is
intended to provide a sufficiently-sized safety database for the
Agency to complete its review of Dynavax's Biologics License
Application (BLA). It will be an 8,000 subject, Phase 3,
observer-blinded, randomized, active-controlled, multicenter trial of
the safety and immunogenicity of HEPLISAV compared with Engerix-B(R)
in adults 18 to 70 years of age.
The primary objectives of HBV-23 will be:
-- To evaluate the overall safety of HEPLISAV with respect to clinically
significant adverse events; and
-- To demonstrate the noninferiority of the peak seroprotection rate
(SPR) induced by HEPLISAV to Engerix-B in subjects with type 2
diabetes mellitus.
HBV-23 will include 5,500 HEPLISAV subjects and 2,500 Engerix-B
subjects, randomized 2:1 and stratified by age and diabetes
diagnosis. HEPLISAV subjects will receive two doses at 0 and 1 month,
while Engerix-B subjects will receive three doses at 0, 1 and 6
months. All HEPLISAV subjects will be evaluated for safety for one
year following the second dose and all potential autoimmune events
will be adjudicated by a Safety Evaluation and Adjudication
Committee. Immunogenicity assessments will be conducted in a subset
of subjects, including those with type 2 diabetes.
"Following extensive discussion with FDA, we've finalized a study
design that we believe will provide confidence to the Agency
regarding HEPLISAV's safety profile, and importantly, will provide
Dynavax with the opportunity to prospectively generate additional
immunogenicity data in persons with diabetes, a population for whom
there is a clear unmet medical need," commented Eddie Gray, Dynavax
Chief Executive Officer.
Dynavax intends to initiate this study in the first quarter of 2014
and conclude subject visits by the end of 2015 and estimates the
external costs of the study to be in the range of $50-55
million.
Dynavax's Marketing Authorization Application for HEPLISAV remains on
file in Europe. The Company is currently preparing its response to
the European Medicines Agency's (EMA) 120-Day List of Questions to be
submitted in the fourth quarter of 2013, following which the EMA will
provide Dynavax its 180-Day List of Outstanding Issues expected in
the first quarter 2014.
The 120-Day response will incorporate the target population for
HEPLISAV and size of the safety database, and will address Good
Manufacturing Practices (GMP) and Good Clinical Practices
(GCP)-related items, including questions arising from a recent EMA
GCP inspection. Dynavax will continue to work through the European
regulatory review process to determine the appropriate next steps,
corrective actions, and possible post-approval commitments. The
Company anticipates that some of these matters will need to be
resolved following issuance of the 180-Day List of Outstanding
Issues, which when received, will enable Dynavax to provide further
clarification on HEPLISAV's potential path forward in Europe.
Engerix-B(R) is a registered trademark of GlaxoSmithKline.
Conference Call Tomorrow
Dynavax management will host a conference call tomorrow at 8:30 a.m.
Eastern Time (5:30 a.m. Pacific Time) and individuals may participate
in the conference call by dialing (866) 428-9517 (domestic) or (224)
357-2389 (international).
To access a live audio webcast of the conference call, please visit
the Company's website at http://investors.dynavax.com/newsevents.cfm
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in